Brief: Veracyte Q2 Revenue USD 130.2 Million Vs. IBES Estimate USD 120.7 Million

Veracyte

06/08/2025 21:05

Overview

Veracyte Q2 revenue rises 14% yr/yr to $130.2 mln, beating expectations

Adjusted EBITDA for Q2 improves 49% to $35.8 mln

Co raises full-year 2025 testing revenue guidance

Outlook

Veracyte raises 2025 testing revenue guidance to $477 mln to $483 mln

Company expects 2025 testing revenue growth of 14% to 15% y/y

Veracyte initiates 2025 total revenue guidance of $496 mln to $504 mln

Company raises 2025 adjusted EBITDA guidance to 23.5% of revenue

Result Drivers

DECIPHER GROWTH - Decipher achieved 28% volume growth, driving revenue increase

AFIRMA VOLUME - Afirma volume met expectations, contributing to testing revenue growth

FRENCH PROCEEDINGS - Resolution of French subsidiary proceedings enabled strategic investments, supporting growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$130.20 mln
$120.70 mln (11 Analysts)
Q2 Net Income
-$1 mln
Q2 Gross Margin
69.0%
Q2 Adjusted Operating Expenses
$60.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Veracyte Inc is $43.00, about 41.8% above its August 5 closing price of $25.01

The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 47 three months ago

Press Release: ID:nBwFP9Tsa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)